last minut gift idea upgrad
year date share significantli under-perform market
view litig concern price
risk/reward attract expect jnj pe expand closer peer market
investor return focus fundament reconsid defens merit
histor macro stock signific rel perform often
associ hc reform recess except past year
think check lot box head leav
risk/reward skew upsid think consensu outlook achiev
there extra week help top-lin growth rate bottom-lin less
dont expect medicare-for-al market extend upsw
investor look defens name find valu past sever
week share resili advers opioid/talc headlin sign
perhap much discount built market may start look
underli fundament fundament posit pharma
continu growth opportun exist portfolio formid pipelin
manag medium-term patent expir devic consum day
bring confid improv outlook
take eleph room opioids/talc reserv offer
made state settl major opioid claim view almost
settlement would posit time unclear talc daubert rule due
day determin expert present bellweth case view sit
hear juli js expert credibl plaintiff less
valuat ep prior in-lin street
trade ep discount vs premium past
yr trade discount peer pharma devic consum
appli pe prior ep reflect blend sotp average
histor rel pe remov prior substanti pe discount litig news flow
quarterli annual ep usd
equal weight
rais usd
return equiti ttm
idc link barclay live interact chart
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ share like
trade fundament next
month trade closer peers/market
believ fundament solid pharma growth
strong driven darzalex imbruvica
stelara tremfya portfolio move posit
medtech/consum allow least
market growth
upsid driver includ capit deploy drive
faster growth greater success new drug
outcom greater margin expans
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
action drug/devic recal margin eros
upgrad overweight
look past year period time share
significantli outperform time period tend
recessionari period owe histor defens natur js busi
convers time market rapidli expand notabl period
under-perform tend period healthcar reformor unwind
fear cours company-specif matter influenc stock well also
significantli drive rel perform would highlight year procrit-eprex
declin cypher competit concern patent expir worri past year
headlin around talc opioid
look ahead litig well understood believ risk/reward
share attract share could return safe-haven statu
pe like expand multipl reflect fundament upgrad
share overweight rate equal weight rais pt
rel price perform
rel pe ntm estim
revenu breakdown divis
pre-tax profit breakdown divis
past year share trade averag pe
in-lin overal show
figur left share trade
year averag stock also trade rel
year averag premium
rel averag premium
figur figur present js revenu pre-tax
profit split recent quarter divis provid
baselin sum-of-the-part framework unlik
conglomer past year follow
stock observ tendenc share trade
premium
sum-of-the-part framework rather
includ tradit conglomer discount put
argument asid share current trade healthi
discount peer across pharma devic consum
share trade ep estim
expect deliv top line growth ep growth
slightli faster depend capit deploy
view bloomberg consensu
estim cover closest peer
visibl growth consensu
estim cover emili field
consensu estim cover next closest
cover
messier engag deal spin-off abbv/bmi
face larg expir timefram
also believ fact larg cap compani
go deal potenti diminish
attract defens name
med-tech see
close peer js current growth rate
slightli slower
compar zbh believ outlook
present js medic devic day point
opportun acceler growth
consum see pg cl
reason comp stock cover
lauren lieberman note howev overal
busi better growth profil
consum compani grow top
line low-singl digit
suggest fair pe use would impli
valuat valuat framework use
eleph room opioid talc
outstand legal liabilitiesmainli talc opioidshav overhang stock
past two year varieti product liabil well believ
litig exposur well understood
 entir websit dedic inform talcum powder safeti
 js johnson babi powder contain talc miner found rock deposit talc
safeti concern new rather concern nearli half centuri
note fda conduct four-year intens investig issu
whether cosmet talc product includ js contamin asbesto
result investig fda conclud none talc use
product contain asbesto contamin concern continu
fda state reason put warn label cosmet talc cite
result studi on-going surveil note fda
test raw talc four talc supplier includ js supplier babi powder
shower-to-show divest fda confirm none contain
asbesto fda review relev bodi scientif literatur conclud
find data submit present conclus evid causal
associ talc use perin area ovarian cancer
cancer societi also opin topic physician data queri pdq
nation cancer institut comprehens sourc inform nci ovarian
fallopian tube primari periton cancer prevent pdq conclud weight
evid support associ perin talc exposur
increas risk ovarian cancer remain sceptic scienc
studi claim associ talc ovarian cancer scienc
individu file claim
 face numer lawsuit claim bodi powder contain talc primarili
johnson babi powder caus cancer js recent period end
septemb disclos plaintiff direct claim file
lawsuit relat talc notabl case date missouri ingham case
includ women juri award plaintiff million compensatori damag
billion punit damag total billion appeal
verdict note date talc case appeal
 note legal brief observ studi
numer meta-analys sever experiment studi publish issu
none studi purport establish causal link talc ovarian cancer
scientif commun taken posit
connect product liabil litig establish accrual defens cost
 accru litig liabilities/settl relat talc
meet fa statement criteria estim loss accru loss probabl
talc-rel lawsuit organ multi-district litig mdl
new jersey court held daubert hear juli parti submit final
round brief court next mileston judg rule expert
present bellweth case expect day
fda test talc asbesto
octob announc receiv test report fda show
sub-trac amount chrysotil asbesto greater singl bottl
johnson babi powder purchas on-line retail voluntarili recal lot
bottl test sampl taken initi investig
identifi possibl sourc contamin
octob subsequ announc new test bottl
previous test fda found asbesto addit bottl lot
also found asbesto test conduct behalf two third-parti lab
sinc compani name lawsuit relat
market opioid lawsuit alleg varieti claim relat opioid market
violat decept act practic fals claim unjust enrich
august state oklahoma vs johnson johnson judg balkman rule
engag fals mislead market caus public nuisanc order pay
million abat follow rule state caus opioid
crisi neither fact law support outcom confid strong ground
appeal appeal rule believ appeal process like take two
year octob judg balkman acknowledg miscalcul js total liabil
judgement revis figur million
octob announc settlement agreement cuyahoga summit counti
ohio ahead feder multi-district litig mdl begin octob
would resolv claim admiss liabil agre pay two counti
combin million settlement payment plu million reimburs counti legal
expens prepar trial addit agre direct million
charit contribut non-profit organ opioid-rel program
octob johnson johnson file announc agre principl
settl opioid litig publicli announc outlin committe state
attorney gener octob wherebi js settlement amount would billion
agreement principl would resolv opioid lawsuit file well futur claim
state citi counti settlement matter would view favor
would view reduc part overhang stock
anoth signific product liabil occur recent year depuy asr hip
system initi world-wide voluntari recal august sinc compani
record total million pre-tax million post-tax charg relat
depuy asr system product liabil accru includ pinnacl
physiomesh composit mesh sinc accru approxim billion legal
expens includ billion associ accrual potenti
settlement opioid litig
end septemb nearli billion cash equival
market secur nearli billion long-term debt among
aaa-credit rate gener roughli million free cash flow per year thu
believ cash posit adequ relat litig matter
devic consum review day
 expect host medic devic consum day highlight busi
innov activ prune portfolio posit divis
april close acquisit auri health billion cash plu
billion mileston relat conting payment auri work
togeth pursu develop robot assist bronchoscop ablat
lesion lung compani enter cooper develop
commerci agreement may goal integr ethicon
neuwav flex microwav ablat technolog system
auri monarch platform receiv fda clearanc march diagnost
per robot pipelin monarch lung biopsi well lung treatment via
ablat oncolyt virus addit compani look applic
endourolog treatment kidney stone well potenti applic gi
februari acquir orthotaxi develop robot platform orthoped
manag expect file approv launch orthotaxi end
american academi orthoped surgeon annual meet march
think march like competit standpoint robot
design minim footprint requir pre-op imag comment
price order magnitud cheaper competitor orthoped robot space
 stryker mako zimmer biomet rosa time tell still plan
 googl form joint ventur develop next-gener surgic robot
advanc toward digit surgeri detail system limit target
launch said earn call focus come
market quickli would rather make sure product differenti
earn call manag note progress updat like provid
juli verb surgic announc kurt azarbarzin join presid chief
execut offic azarbarzin previous serv chief technolog offic
previous found surgiquest serv ceo
compani acquir also experi tyco healthcar
covidien surgic
turn around orthoped key prioriti
 js depuy synth orthoped busi report million sale
repres js medic devic divis maintain top market share
posit major orthoped segment
addit robot knee believ innov help improv growth
trajectori orthoped launch attun cementless knee rotat platform
option septemb plan launch cementless fix bear knee fiscal
compani view new platform pivot return knee market
perform addit believ stabil declin market share spine
identifi three mean return growth focus top countri
shore commerci execut concentr degen disk diseas
deform complex cervic septemb launch conduit interbodi cage
degen disk diseas plan launch symphoni system complex
consum opportun margin improv
 hyper-focus person consum health manag see credo-bas
cultur talent leadership qualiti complianc agil innov model focu
brand root scienc endors profession focu drive
profit growth part algorithm success
manag believ well-posit see acceler across three broad
segment self-car over-the-count skin health beauti skin health specialti
babi oral wound women health collect period
consum market compet expect increas compound-annual-growth-rate
 believ macro trend support individu focus health
digit creat new opportun demand person
 focus innov tylenol dissolv pack johnson cotton touch
formul babi categori also look acquisit growth acquir
ogx zarbe dr ci labo track well
believ js pharmaceut busi grow least in-lin overal
growth rate market next year assum major legisl
price chang continu see strong growth stelara tremfya darzalex
imbruvica pharma day last may highlight expect launch
nme billion potenti along dozen product line
term major patent expir ahead next major one stelara us sept
eu jan simponi us feb eu april although biolog
time biosimilar entri less clearparticularli stelara simponi
crowd marketplac humira biosimilar enter market
xarelto us composit matter patent expir august howev
understand agreement gener compani launch year
date view dont see patent expir signific issu
stock year
way context today ww simponi/simponi aria sale billion
sale ww stelara sale billion grow rapidli sale
xarelto sale billion sale
sale street estim driven strength pharmaceut
medic devic ep street estim
estim rais full-year organ sale guidanc
adjust ep guidanc
net/net despit impress beat rais maintain equal weight
litig may remain overhang stock
addit detail quarter
million except per share data chang sale constant currenc underli basi unless otherwis note
 rais full-year organ sale guidanc adjust ep
guidanc
sever js drug continu report robust sale growth includ stelara
darzalex imbruvica tremfya invega/sustenna
simponi/simponi aria erleada uptravi
opsumit also expect continu grow pharma franchis
market
medic devic organ growth continu improv exclud
impact benefit buy-in ahead japanes consumpt tax
strongest year
 provid earli commentari note expect grow ep
least line revenu growth
 continu face pressur gener biosimilar remicad
 zytiga velcad
 continu lose share knee albeit less
knee growth help off-set declin
minim increment updat given regard litig remain
overhang stock make addit litig accrual
gross margin sale y/i
sg sale y/i reflect js cost contain
measur priorit spend
 sale y/i primarili driven invest medic
devic particularli robotics/digit surgeri program key growth platform
oper margin y/i
adjust tax rate y/i driven adjust exist tax
adjust ep street estim estim
 rais full-year organ sale growth guidanc constant currenc sale growth guidanc
full-year rais report sale growth guidanc rais
manag also rais low-end full-year tax rate guidanc full-year adjust ep
expect rais
manag plan releas formal guidanc along result januari howev manag provid
commentari around segment note expect pharma deliv above-market growth continu sale
momentum medic devic improv profit portfolio optim consum expect incom
approxim half level record effect tax rate rang net/net ep growth
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
